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Abstract
Background: The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is activated in tumor cells and promotes tumor
cell survival after radiation-induced DNA damage. Because the pathway may not be completely inhibited after
blockade of PI3K itself, due to feedback through mammalian target of rapamycin (mTOR), more effective inhibition
might be expected by targeting both PI3K and mTOR inhibition.
Materials and methods: We investigated the effect of two dual PI3K/mTOR (both mTORC1 and mTORC2)
inhibitors, NVP-BEZ235 and NVP-BGT226, on SQ20B laryngeal and FaDu hypopharyngeal cancer cells characterised
by EGFR overexpression, on T24 bladder tumor cell lines with H-Ras mutation and on endothelial cells. Analysis of
target protein phosphorylation, clonogenic survival, number of residual gH2AX foci, cell cycle and apoptosis after
radiation was performed in both tumor and endothelial cells. In vitro angiogenesis assays were conducted as well.
Results: Both compounds effectively inhibited phosphorylation of Akt, mTOR and S6 target proteins and reduced
clonogenic survival in irradiated tumor cells. Persistence of DNA damage, as evidenced by increased number of
gH2AX foci, was detected after irradiation in the presence of PI3K/mTOR inhibition, together with enhanced G2 cell
cycle delay. Treatment with one of the inhibitors, NVP-BEZ235, also resulted in decreased clonogenicity after
irradiation of tumor cells under hypoxic conditions. In addition, NVP-BEZ235 blocked VEGF- and IR-induced Akt
phosphorylation and increased radiation killing in human umbilical venous endothelial cells (HUVEC) and human
dermal microvascular dermal cells (HDMVC). NVP-BEZ235 inhibited VEGF-induced cell migration and capillary tube
formation in vitro and enhanced the antivascular effect of irradiation. Treatment with NVP-BEZ235 moderately
increased apoptosis in SQ20B and HUVEC cells but not in FaDu cells, and increased necrosis in both tumor and
endothelial all cells tumor.
Conclusions: The results of this study demonstrate that PI3K/mTOR inhibitors can enhance radiation-induced
killing in tumor and endothelial cells and may be of benefit when combined with radiotherapy.
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Radiotherapy is one of the most important modalities
for the management of cancer. However, despite pro-
gress in radiation technology and significant gains
achieved with the use of combined radio-chemotherapy,
there is a substantial proportion of patients that fail to
achieve long-term control [1]. The latter provides a
strong rationale for combining molecular targets with
radiation to improve patient outcome.
The phosphatidylinositol 3-kinase (PI3K)/Akt/mam-
malian target of rapamycin (mTOR) pathway controls
tumor cell proliferation, growth, and survival after DNA
damage [2]. Activation of this pathway is frequent in
many cancers and can occur through diverse mechan-
isms such as amplification of the epidermal growth fac-
tor receptor (EGFR) gene, mutations of the Ras
oncogene, PI3K mutations and loss of phosphatase and
tensin homologue deleted in chromosome 10 (PTEN)
[1-3]. This pathway consists of EGFR/Ras/PI3K/Akt and
is a prime target for inhibition in the context of radio-
therapy [4-6]. We and others have previously shown
that inhibition of the EGFR/Ras/PI3K/Akt pathway can
increase susceptibility to radiation-induced tumor killing
[3,7-11]. Inhibition of Ras, PI3 kinase and Akt reduce
tumor clonogenic survival after radiation at clinically
relevant doses [3-5,7,10,12]. A phase III randomized
clinical trial evaluated the addition of cetuximab, an
EGFR inhibitor, to radiotherapy and demonstrated
improved overall survival in the combined modality arm
over radiation alone [13].
T h ek i n a s em T O Rc o n s i s t so fT O R C 1a n dT O R C 2 ,
two functionally distinct multiprotein complexes [14].
TORC1 includes mTOR and raptor (regulatory-asso-
ciated protein of mTOR). TORC2 is composed of
mTOR and rictor (rapamycin-insensitive companion of
TOR) and regulates the activity of Akt [14]. mTOR inhi-
bitors have radiosensitising potential in tumor and vas-
cular cells [15,16]. Inhibition of TORC1 activity alone
can result in TORC2-mediated feedback phosphoryla-
tion of Akt on Ser473 [14,17]. The paradoxical feedback
activation of the PI3K/Akt pathway may compromise
the efficacy of TORC1 inhibitors and provide the ratio-
nale for generating dual inhibitors.
Preclinical studies have demonstrated antitumor activity
for the PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235) in
a variety of models especially those with PI3K mutation
or K-Ras mutation [18,19]. Here, we examined whether
the PI3K/mTOR (both mTORC1 and mTORC2) inhibi-
tors BEZ235 and NVP-BGT226 (BGT226) could sensitise
tumor cells with EGFR overexpression or Ras mutation
to radiation. We investigated two inhibitors to get a bet-
t e ri n s i g h to ft h ee f f i c a c yo fe a c hc o m p o u n da n dt e s t
whether comparable results will be obtained. Both dual
PI3K/mTOR inhibitors are issued from the same chemi-
cal space (Imidazo-quinolines). BGT226 displays more
prolonged effects on target in cells, likely due the slow
kinetics on target (high affinity, slow release). Addition-
ally, we studied how PI3K/mTOR inhibition can modify
the response of endothelial cells after IR. A substantial
body of evidence has demonstrated that the PI3K/mTOR
pathway is involved in angiogenesis and functions down-
stream of vascular endothelial growth factor (VEGF) to
promote endothelial cell survival [20-22]. We therefore
tested the impact of one the inhibitors, BEZ235, on
VEGF-mediated Akt signaling, survival and in vitro
angiogenesis in irradiated tumor and endothelial cells.
Methods
Cell culture
T24 bladder and FaDu hypopharyngeal cancer cell lines
were obtained from ATCC. SQ20B laryngeal squamous
cell carcinoma cells were obtained from Dr. Ralph
Weichselbaum (University of Chicago, Chicago, IL).
Tumor cells were cultured as described [7]. Human
umbilical vein endothelial cells (HUVEC) and human
dermal microvascular cells (HDMVC) were purchased
from Lonza and were maintained in EGM-2 medium
(Lonza) supplemented with EGM-2 SingleQuots (Lonza)
at 37°C in water saturated 5% CO2/95% air.
Dual PI3K/mTOR inhibitors treatment
BGT226 and BEZ235 dual PI3K/mTOR inhibitors were
obtained from Novartis Pharma AG. The drugs were
added to mid-log phase cell cultures. After treatment,
medium was replaced with drug-free medium. For the
control group, equal amounts of DMSO were used.
Clonogenic survival assay
The effect of BEZ235 (50 nmol/L) and BGT226 (5 nmol/
L) on tumor cell survival after irradiation was assessed by
clonogenic assay, as previously reported [7]. Different
drug-radiation schedules were tested (see “Results”). In
HUVEC and HDMVC, BEZ235 (50 nmol/L) was added 1
h before radiation and medium was replaced by basal
medium containing 1.5% FCS and a constant concentra-
tion of VEGF (10 ng/ml) at 1 h post-irradiation [23].
We also assessed clonogenicity in tumor cells cultured
in hypoxia after treatment with one of the PI3K/mTOR
inhibitors, BEZ235 (50 nmol/L). For the clonogenic
assays performed in hypoxia, tumor cells were incubated
in 0.5% O2 using an InVivo2 300 chamber (Ruskinn
Technology, UK), for 6 h before irradiation under
hypoxic conditions using tightly sealed chambers. The
target O2 level was achieved within 6 h of gassing and
maintained during irradiation, as confirmed by an Oxy-
Lite oxygen probe (Oxford Optronix). Tumor cells
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h post-irradiation. As standard, BEZ235 was added 1 h
prior to irradiation and was washed away 17 h after
irradiation.
Analysis of protein phosphorylation
Immunoblotting was performed as described elsewhere
[7]. Blocking was performed by 5% bovine serum albu-
min for phospho-specific antibodies. Phospho-mTOR
(ser-2448), phospho-Akt (ser-473) and phospho-S6 (ser-
235/236) primary antibodies (Cell Signaling) were used
at 1:1,000 dilution. b-actin clone AC-15 (Sigma) was
used at 1:4,000 dilution. Antibody binding was detected
with enhanced chemiluminescence kit (GE-Amersham).
Analysis of gH2AX foci
Residual DNA damage in irradiated FaDu and SQ20B
cells was assessed by measuring residual gH2AX foci.
Cells were pretreated with either BGT226 (5 nmol/L) or
BEZ235 (50 nmol/L) for 1 h before radiation (4 Gy) and
the number of residual foci was determined at 24 hpost-
irradiation as previously described [7]. Cells were
exposed to PI3K/mTOR inhibitor for up to 24 h post-
irradiation. Cells were also treated separately with the
BEZ235 (50 nmol/L) and radiation (4 Gy), as above, and
a time-course analysis of residual gH2AX foci was per-
formed at 6, 24 and 48 h post-irradiation.
The number of residual DNA damage foci was also
measured in HUVEC at 24 h post-irradiation (4 Gy).
HUVEC were pretreated with BEZ235 (50 nmol/L) for 1
h before irradiation. Following irradiation, medium was
replaced by basal medium containing 1.5% FCS and 10
ng/ml VEGF.
Cell cycle assay
FaDu, SQ20B and HUVEC cells were plated into T25
tissue culture flasks (Falcon) and incubated overnight to
allow cells to reach mid-log phase. Tumor cells were
treated with BEZ235 (50 nmol/L) for 1 h before irradia-
tion and medium was replaced 17 h post-irradiation.
HUVEC cells were plated in growth-factor depleted
medium overnight. Cells were treated with BEZ235 (50
nmol/L) 1 h before irradiation with a single dose of 4
Gy. Following irradiation, HUVEC medium was replaced
by basal medium containing 1.5% FCS and a constant
concentration of VEGF (10 ng/ml). All cells were trypsi-
nized using 0.5% Trypsin/EDTA (Life Technologies-
Bethesda Research Laboratories) and centrifuged at 1200
rpm. Thereafter, they were washed with PBS, resus-
pended in 1 mL ice cold 70% ethanol and centrifuged
again at 1,200 rpm for 10 min. Following this, they were
incubated with a mixture of 200 μg/mL RNaseA diluted
in PBS with 50 μg/mL propidium iodide (PI), for 30 min
at room temperature, in a dark room. Cell cycle was
examined 24 h post-irradiation using a Becton Dickin-
son FACSort machine with the Modfit LT analysis soft-
ware. Data are representative of three independent
experiments.
Analysis of apoptosis
FaDu, SQ20B and HUVEC cells were plated into T25
tissue culture flasks (Falcon) and incubated overnight to
allow cells to reach mid-log phase. Tumor cells were
treated with PI3K/mTOR inhibitor for 1 h before irra-
diation. Medium was replaced 17 h post-irradiation.
HUVEC cells were plated in growth-factor depleted
medium overnight. Cells were treated with BEZ235 (50
nmol/L) 1 h before irradiation with a single dose of 4
Gy. In tumor cells, fresh medium was replaced 17 h
post-irradiation. Similarly to the cell cycle assay, follow-
ing irradiation, HUVEC medium was replaced by basal
medium containing 1.5% FCS and a constant concentra-
tion of VEGF (10 ng/ml). Cells were allowed to grow
and were finally trypsinized at 24 and 48 h post-irradia-
tion. Apoptosis was analyzed by flow cytometry using
FITC Annexin V apoptosis detection kit I (BD Pharmin-
gen) in combination with PI staining, according to the
manufacturer’s instructions. Analysis of the data was
conducted with the FlowJo 7.5 analysis software (Tree
Star, Oregon Corporation).
Capillary tube formation and endothelial cell migration
H U V E Ca n dH D M V Ci nm i d - l o gp h a s ew e r ep l a t e di n
growth-factor depleted medium overnight and treated
with BEZ235 (50 nmol/L) for 1 h, before irradiation
with 4 Gy. Cells were trypsinized immediately after irra-
diation and plated onto 24-well plates, previously coated
with Matrigel (300 μL per well; BD Biosciences), and
incubated in basal medium containing 1.5% FCS and a
constant concentration of VEGF (10 ng/ml). Once
tubules began to form in the control group, cells were
stained with calcein (BD Biosciences, Germany), accord-
ing to the manufacturer’s instructions. Three randomly
selected digital microphotographs (magnification × 10
for HUVEC and x4 for HDMVC) were obtained from
each well. The length of capillary-like tubular structures
was measured with the ImageJ software and was nor-
malized to the control group. Experiments were per-
formed twice in quadruplicates.
For the migration assay, cells were trypsinized immedi-
ately after irradiation and plated onto the top chamber of
24-well plates (60,000 HUVEC and 30,000 HDMVC/well)
with 8 μm matrigel-coated inserts (BD Biosciences). Basal
medium (500 μL) containing 1.5% FCS and a constant
concentration of VEGF (10 ng/ml) was added to the
lower compartment, and cells were incubated for 18 h
and allowed to migrate towards the VEGF-containing
medium, according to the manufacturer’s instructions.
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membrane with a cotton swab and migrated cells were
stained with calcein fluorescent dye (BD Biosciences).
Three randomly selected digital microphotographs were
obtained from each well. The number of migrated
endothelial cells (lower side of the membrane) per field
(magnification × 10) was counted by microscopy. The
results represent the mean number of migrated cells, nor-
malized to the control group, as calculated from 3 ran-
dom fields in quadruplicates.
Statistical analyses
The values were expressed as means ± SD. The signifi-
cance of differences between the means was measured
by two-tailed t-test or one-way ANOVA using the
GraphPad Prism program version 4.0 (GraphPad Soft-
ware, USA). A value p < 0.05 was considered statistically
significant.
Results
BGT226 and BEZ235 inhibit PI3K and mTOR activity and
reduce AKT and S-6 phosphorylation
We initially aimed to confirm inhibition of PI3K and
mTOR by these novel compounds and to establish their
minimum inhibitory concentrations. To this end, we
analysed the phosphorylation of PI3K pathway down-
stream targets by Western blotting after treatment of
SQ20B cells with BGT226 and BEZ235 in increasing
concentrations (Figure 1A). BGT226 and BEZ235 were
able to inhibit phosphorylation of Ser473 Akt, Ser2448
mTOR, and Ser240/244 S6 in SQ20B cells at concentra-
tions of 5 nmol/L and 50 nmol/L, respectively (Figure
1A). BEZ235 (50 nmol/L) inhibited phosphorylation of
all three targets within 1 h of exposure. Inhibition per-
sisted for at least 24 h. Inhibition of pAKT by BGT226
(5 nmol/L) was relieved after 16 h (Figure 1B). Signal-
ling inhibition occurred in irradiated cells as well (Figure
1C and 1D).
The dual PI3K/mTOR inhibitors reduce radiation survival
of tumor cells with EGFR overexpression or Ras mutation
SQ20B and FaDu are derived from head and neck can-
cers with overexpression of EGFR. T24 is a bladder can-
cer cell line with mutated H-Ras. We conducted
experiments in order to assess the optimal drug incuba-
tion time for colony forming assays with BEZ235 (50
nmol/L) and BGT226 (5 nmol/L) in SQ20B,T24 and
FaDu cells in the absence of radiation. Exposure of cells
to the drugs for 18 h did not alter plating efficiency
(PE) significantly (Figure 1E). Therefore, for subsequent
clonogenic assays, cells were pretreated with either com-
pound for 1 h before irradiation and total incubation
time was limited to 18 h. BGT226 and BEZ235 treat-
ment for 18 h resulted in significant reduction in
clonogenic survival after irradiation in all three cell lines
(Figure 1F). To quantify the effect, the radiation dose
required to reduce the surviving fraction to 10% was cal-
culated (dose modifying factor 10%; DMF10). The ratio
of DMF10 in control cells to BGT226-treated cells was
calculated to be 2.6 for SQ20B, 1.6 for FaDu and 1.7 for
T24. In BEZ235-treated cells, the DMF10 was 2.5 for
SQ20B, 1.5 for FaDu and 1.7 for T24. Thus, there is sig-
nificant radiosensitisation of these three cell lines by
these inhibitors.
To understand the mechanisms of radiosensitisation,
we investigated BGT226- and BEZ235-induced enhance-
ment of radiation response in the post-irradiation set-
ting. BGT226 (5 nmol/L) or BEZ235 (50 nmol/L) were
added to the culture medium of SQ20 and T24 cells
immediately or 6 h after exposure to radiation, for a
total exposure time of 18 h. Treatment with drug imme-
diately after irradiation was similar to giving the drug
before (Additional file 1: Figure S1A) but if given 6 h
after exposure, no radiosensitizing effect was observed
(Additional file 1: Figure S1B). The latter indicates that
blockade of the PI3K/mTOR pathway early before or
after irradiation is necessary for sensitizing tumor cells
to radiation damage.
BEZ235 radiosensitises tumor cells under hypoxic
conditions
Because hypoxic cells can be up to three fold more radio-
resistant than normoxic cells [1], we asked whether the
radiosensitising effect of BEZ235 can still be seen under
hypoxic conditions (Additional file 2: Figure S2A-B).
Tumor cells were treated with one of the inhibitors,
BEZ235 (50 nmol/L) for 1 h before up to 17 h after irra-
diation under hypoxic conditions (0.5% oxygen). Treat-
ment with BEZ235 in the absence of irradiation did not
result in significant toxicity in hypoxia (data not shown).
Addition of BEZ235 reduced post-irradiation survival sig-
nificantly for all three cell lines in hypoxia (Additional
file 2: Figure S2A). All cell lines showed increased radio-
resistance under hypoxic conditions, as compared to nor-
moxia, confirming the hypoxic effect in our experimental
settings (Additional file 2: Figure S2B). These results
show that PI3K/mTOR inhibition can radiosensitise
tumor cells in normoxic as well as hypoxic conditions.
BEZ235 induces apoptosis in SQ20B cells and increases
necrosis
We analysed apoptosis in FaDu and SQ20B cells upon
administration of BEZ235 (50 nmol/L), in combination
with irradiation (4 Gy) (Figure 2A-B). We did not
observe any increase in apoptosis in FaDu cells after
treatment with BEZ235 alone at either time point while
necrosis was increased, especially at 48 h post-irradia-
tion. In contrast, BEZ235 increased both apoptosis and
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C
E
B
D
F
Figure 1 BGT226 and BEZ235 attenuate oncogenic signaling and reduce clonogenic survival after radiation. SQ20B cells were exposed
to the indicated drugs for 1 h and evaluated by Western blotting for phosphorylation of mTOR (Ser2448), Akt (Ser-473) and S6 protein (ser-235/
236). b-actin was used as a loading control. A, Dose response of the PI3K/mTOR pathway in SQ20B cells after 1 h exposure to the indicated
drug. B, Time-course of PI3K/mTOR inhibition to indicated drugs at maximal effective doses. C-D, Response of PI3K/mTOR pathway 1 h after 4
Gy. Cells were treated with 5 nmol/L BGT226 (C) or 50 nmol/L BEZ235 (D) for 1 h before and 1 h after irradiation. E, Plating efficiency of SQ20B,
T24 and FaDu cells after exposure to indicated drugs for 1 h before up to 17 h post-irradiation (n = 3). F, Clonogenic survival of indicated cell
lines after 18 h treatment with BEZ235 (50 nmol/L) and BGT226 (5 nmol/L), as described in “Methods” (n = 3). P < 0.05; **, P < 0.01 over DMSO-
treated control.
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tion alone enhanced necrosis at 48 h post-irradiation in
FaDu and SQ20B cells. (Figure 2A-B). The addition of
BEZ235 to radiation did not increase apoptosis in either
cell line. Only a slight increase in necrosis was observed
at 48 h post-irradiation in both cell lines.
Radiosensitisation induced by the dual PI3K/mTOR
inhibitors is accompanied by persistence of gH2AX foci
and cell cycle arrest
To gain insight into the molecular mechanisms of radio-
sensitization of both compounds, we investigated the
effect of these drugs on the DNA damage response by
measuring the number of gH2AX foci at different time
points post-irradiation (4 Gy). A higher number of resi-
dual gH2AX foci was detected after treatment with
BGT226 (5 nmol/L) and BEZ235 (50 nmol/L) as com-
pared with radiation alone, at 24 h post-irradiation (Fig-
ure 3A-B). We confirmed the higher number of foci
after treatment of cells with BEZ235 at different time
points post-irradiation in tumor cells (Additional file 3:
Figure S3A-B). Although the number of foci decreases
more rapidly in FaDu after radiation alone, the trend at
12, 24 and 48 h is similar for both FaDu and SQ20B
cells and reveals approximately twice as many foci in
the combination group, as compared to radiation alone.
We also investigated the impact of PI3K/mTOR inhi-
bition on cell cycle distribution. Treatment with BEZ235
(50 nmol/L) for 1 h before irradiation up to 17 h after
led to an increased percentage of cells in G1 phase
while S decreased, indicating a G1 block. Irradiation of
FaDu cells led to a G2 block that was substantially
increased after treatment with the inhibitor (Figure 3C).
Similar effects were obtained from SQ20B cells even
though the increase in G2 phase delay in the combina-
tion group was less dramatic (Figure 3D). The profound
G2 block observed in the combination group underlines
the radiosensitizing potential of these drugs.
BEZ235 blocks PI3K/mTOR signaling and sensitizes
endothelial cells to irradiation
Next we wanted to investigate the effect the dual PI3K/
mTOR inhibitors in endothelial cells. To this end, we
determined the effect of irradiation and VEGF on the
PI3K signalling pathway in HUVEC using BEZ235 (50
nmol/L). In endothelial (HUVEC) cells, Akt was phos-
phorylated 1 h after irradiation (4 Gy) or exposure to
VEGF-containing medium (10 ng/mL) (Figure 4A;
+VEGF). HUVEC exposed to growth factor-depleted
medium did not show Akt phosphorylation (Figure 4A;
-VEGF). Pre-treatment of HUVEC with BEZ235 led to
complete abrogation of PI3K/Akt/mTOR signalling, in
irradiated and unirradiated HUVEC (Figure 4A). Treat-
ment of HUVEC cells with BEZ235 (50 nmol/L) for 1 h
before up to 1 h after irradiation significantly reduced
clonogenic survival in HUVEC (Figure 4B). A similar
decrease in clonogenicity was observed in HDMVC,
cells that more closely resemble tumor microvascular
cells (Figure 4B).
BEZ235 increases DNA damage and necrosis in
irradiated endothelial cells
We analysed DNA damage in irradiated cells pretreated
with BEZ235 (50 nmol/L) in response to VEGF (10 ng/
AB
Figure 2 Evaluation of apoptosis in irradiated tumor cells treated. A-B, Cells were treated with BEZ235 (50 nmol/L). 4 Gy was given after 1
h of drug treatment, with the drug maintained for an additional of 17 h. Apoptosis was assessed by flow cytometry for Annexin V combined
with propidium iodide, at 24 and 48 h post-irradiation (n = 2).
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resulted in enhanced persistence of gH2AX foci 24 h
after exposure to 4 Gy irradiation (Figure 5A). In addi-
tion, BEZ235 treatment only slightly increased apoptosis
and necrosis at 24 and 48 h and enhanced radiation-
induced necrosis, especially at 24 h post-irradiation
(Figure 5B). Radiation alone increased necrosis 48 h
after radiation. (Figure 5B).
A
C
D
B
Figure 3 Evaluation of residual DNA damage and cell cycle distribution in irradiated tumor cells. A-B, gH2AX foci at 24 h post-irradiation.
Indicated cell lines were exposed to 5 nmol/L BGT226 or 50 nmol/L BEZ235 for 1 h followed by irradiation with 4 Gy. Drugs were left until
staining was performed. Residual gH2AX foci were counted 24 h later. C-D, Cells were treated as in (A) and cell cycle distribution was
determined by flow cytometry after exposure to propidium iodide 24 h post-irradiation (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001 over
DMSO-treated control.
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irradiated endothelial cells
To determine whether Akt/mTOR inhibition affects the
formation of vascular networks by endothelial cells, a
tube formation assay was performed as described in
Materials and Methods. BEZ235 (50 nmol/L) or irradia-
tion alone (4 Gy) decreased tube formation in both
HUVEC and HDMVC and resulted in shorter tubular
structures with fewer interconnection branching points
(Figure 6A-B). The combination of BEZ235 with irradia-
tion further potentiated the reduction (Figure 6A-B).
For the migration assay, cells were treated in a similar
way as in the tube formation assay and were allowed to
migrate to the lower compartment of a transwell chamber.
BEZ235 (50 nmol/L) and irradiation (4 Gy) significantly
reduced migration of HUVEC and HDMVC (Figure 6C-
D). Addition of BEZ235 to radiation revealed inhibition of
endothelial cells migration (Figure 6C-D). Therefore, dual
PI3K/mTOR inhibition can enhance the antivascular effect
of radiation in culture.
Discussion
Our past work and that of others point to increased
PI3K/Akt/mTOR signalling as a mediator of enhanced
tumor survival after radiation-induced DNA damage
[3,7,9,24]. Deregulation of mTOR signalling has also
been implicated in response to radiation [14]. Rapalogs
have antiproliferative effects in vitro but their efficacy in
tumors with PI3K/Akt and mTOR activation has been
limited. There is extensive crosstalk between the two
A
B
Figure 4 PI3K/mTOR inhibition affects downstream signaling and clonogenic survival in irradiated vascular endothelial cells. A, HUVEC
were starved overnight and were treated with 50 nmol/L BEZ235 for 1 h before irradiation (4 Gy). Following irradiation, medium was replaced
by either basal medium containing 1.5% FCS and 10 ng/ml VEGF (+VEGF) or growth factor-depleted medium (-VEGF). Cell lysates were collected
1 h post-irradiation and subjected to Western blot analysis. B, Clonogenic survival of HUVEC and HDMVC treated with BEZ235 (50 nmol/L) for 1
h before irradiation up to 1 h post-irradiation (n = 3). *, P < 0.05; **, P < 0.01 over DMSO-treated control.
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signalling through the S6K-IRS1 feedback loop and
induce Akt phosphorylation by mTORC2 [14,25].
Because rapalogs inhibit only the mTORC1 complex,
paradoxical activation of Akt can limit their therapeutic
potential. Here we have shown that PI3K/mTOR dual
inhibitors effectively block downstream targets and
result in radiation sensitization in tumor cell lines and
in endothelial cells. Interestingly, PI3K/mTOR inhibition
resulted in decreased clonogenicity in cells radiated in
hypoxia. These data indicate that dual PI3K/mTOR inhi-
bition might prevent PI3K pathway reactivation and
further enhance radiation-induced cell killing.
Several preclinical studies have found promising activ-
ity for the dual PI3K/mTOR inhibitor BEZ235 against
various tumors [18,19] especially those with mutations
i nP I 3 K .I nt h ep r e s e n ts t u d y ,d u a li n h i b i t o r sl e dt o
radiosensitization of tumor cells and of endothelium.
The efficacy of these compounds should apply to tumor
cells with a wide spectrum of oncogenic lesions because
the Ras/EGFR/PI3K/mTOR pathway is activated in
many types of cancer. Both BGT226 and BEZ235
enhanced the radiosensitivity of SQ20B cells and T24
cells when added before or immediately after radiation
but not after 6 h. These findings may support schedul-
ing strategies for future clinical trials testing the radio-
sensitising potential of these compounds.
To determine whether radiosensitisation was asso-
ciated with inhibitor-mediated cell cycle redistribution,
we analysed cycle distribution in cells pretreated with
one of the dual inhibitors, BEZ235. Treatment of FaDu
and SQ20B cells with BEZ235 alone resulted in growth
arrest in the G1 phase.. This is similar to the observation
reported in several studies investigating BEZ235 and
other PI3K inhibitors [18,26-28]. Importantly, when cells
were irradiated after BEZ235 pretreatment, the percen-
tage of SQ20B and FaDu cells in G2 phase was
increased by approximately 3-fold and 4.5-fold, respec-
tively. This finding concurs with our previous report on
PI3K inhibitor, PI-103 where a ~2-fold increase in G2
phase population arrest was recorded [7]. Notably, rapa-
l o g sa r ek n o w nt oi n d u c eaG 2 block when combined
with irradiation [14].
We also investigated the effect of dual PI3K/mTOR
inhibition in apoptosis. BEZ235 increased necrosis but
not apoptosis in FaDu cells. In contrast, BEZ235
enhanced both apoptosis and necrosis in SQ20B cells.
In the combination group, there was no increased apop-
t o s i si ne i t h e rc e l ll i n ea n do n l yas l i g h ti n c r e a s ei n
necrosis was observed at 48 h post-irradiation. Previous
studies have demonstrated increased apoptosis after
treatment with BEZ235 in some tumor cell lines and
lack of apoptosis induction in others. For instance there
was no apoptosis induction in glioma or melanoma cell
lines [26,27]. There is however in lung cancer, sarcoma
and leukemia [28-30].
Hypoxic cells are 2 to 3-fold more resistant than oxic
cells to radiation and tumor hypoxia is associated with
treatment failure following radical radiotherapy [1]. We
were therefore interested to investigate the efficacy of
BEZ235 in the context of hypoxia. As expected, hypoxia
resulted in increased radioresistance of FaDu, SQ20B
A B
Figure 5 PI3K/mTOR inhibition enhances DNA damage in irradiated HUVEC. A, apoptosis assessment in HUVEC treated with BEZ235 and/or
radiation. Previously starved HUVEC were treated with BEZ235 (50 nmol/L) for 1 h before irradiation. The medium was removed immediately
following irradiation and was replaced by basal medium containing 1.5% FCS and a constant concentration of VEGF (10 ng/ml).. Annexin
V-propidium iodide flow cytometry was used to identify cells in apoptosis or necrosis 72 h after irradiation. B, mean gH2AX foci number in
HUVEC cells treated with BEZ235 (as above) and radiation at 24 h post-irradiation (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001 over DMSO-
treated control.
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Figure 6 PI3K/mTOR inhibition attenuates tubule formation and migration by irradiated HUVEC and HDMVC. Cells were exposed to
BEZ235 (50 nmol/L) for 1 h, before irradiation with 4 Gy. Cells were trypsinized immediately after irradiation and were incubated in basal medium
containing 1.5% FCS and a constant concentration of VEGF (10 ng/ml). A, representative images of capillary tubule formation in HUVEC (left) and
HDMVC (right) in response to BEZ235 (50 nmol/L). B, quantification of tubule formation as measured by the length of capillary-like tubular
structures and normalized to the control group (4 power fields per sample). C, representative images of HUVEC (left) and HDMVC (right) migration
18 h post-irradiation. D, endothelial cell migration of indicated cells (treated as above). The number of migrated cells per power field (10X) was
counted (12 fields per group) and normalized to the control group (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001 over DMSO-treated control.
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BEZ235 led to significant sensitization of hypoxic cells
to radiation and therefore this drug can be an attractive
adjunct for radiotherapy.
BEZ235 and BGT226 enhanced persistence of residual
gH2AX foci after irradiation. gH2AX foci were also mod-
erately increased in cells treated with BEZ235 alone,
which could be attributed to the potentially toxic effect
of the compounds, leading to enhanced DNA damage
even in the unirradiated cells. Selective inhibition of the
PI3K pathway using siRNA leads to significant radiosensi-
tization of tumor cells. Therefore, the radiosensitizing
effect of PI3K/mTOR inhibitors cannot be wholly attribu-
ted to inhibition of other targets ("off-target” effect). Pre-
vious evidence has demonstrated that inhibition of the
PI3K pathway can affect formation of gH2AX foci, even
in the absence of radiation [7]. These indicate that PI3K/
mTOR plays a role in DNA repair after the initial injury.
Our results are in accordance to the work of Konstantini-
dou et al. [29]. Similar findings have been also been
described before for different PI3K inhibitors [7,31].
The PI3K/Akt/mTOR intercept node is involved in
endothelial signaling response to upstream effectors
such as VEGF [22]. Chronic Akt activation in endothe-
lial cells recapitulated the salient features of tumor vas-
culature [32]. In VEGF-stimulated porcine aortic
endothelial cells and HUVEC, VEGFR2 recruited the
p110/p85 complex and increased their proliferation
[33]. PI3K/Akt/mTOR activation can occur upon expo-
sure to radiation in endothelial cells [22]. Overexpres-
sion of Akt in endothelial cells resulted in abnormal
vascular remodeling with embryonic lethality [34].
Here BEZ235 blocked VEGF- and irradiation-induced
activation of Akt phosphorylation and significantly
enhanced cell death in vascular and microvascular
endothelial cells. Furthermore, BEZ235 reduced VEGF-
mediated migration and tube formation and enhanced
the antivascular effect of radiation in endothelial cells.
We observed a slight increase in apoptosis and necrosis
in BEZ235-treated endothelial cells. BEZ235 increased
radiation-induced necrosis, especially at 24 h post-irra-
diation. Our findings are in accordance with previous
reports showing that PI3K and/or mTOR blockade can
exert an antivascular activity [15,22,35]. The mTOR
inhibitor rapamycin decreased VEGF-mediated growth
of endothelial cells and activation of Akt/mTOR signal-
ing after irradiation and enhanced the antivascular effi-
cacy of radiotherapy [15,16,22]. The fact that dual
inhibition of PI3K/mTOR pathway can increase the
antivascular effect of radiation in endothelial cells is an
important finding. First, PI3K/mTOR inhibition by
BEZ235 alone can result in alterations in tumor blood
vessel morphology andfunctionality but this appears to
be a dose-dependent effect and can affect the efficacy
of radiotherapy significantly, as recently demonstrated
by our group [36]. Secondly, the enhanced radiosensiti-
zation of endothelial cells conferred by BEZ235 would
imply that dual PI3K/mTOR inhibition could, in the-
ory, enhance normal tissue damage and therefore spe-
cial caution is required before proceeding with clinical
studies using these agents in combination with
radiation.
Conclusions
In summary, we demonstrated that PI3K/mTOR dual
inhibitors are effective radiosensitisers in tumor cells
with EGFR overexpression or oncogenic Ras mutation.
BEZ235 sensitized tumor cells to radiation under both
normoxic and hypoxic conditions. The antivascular
activity reported represents a clear advance in under-
standing the properties of dual PI3K/mTOR inhibition.
Altogether, our data indicate that direct inhibition of
PI3K/mTOR activity may be of benefit when combined
with radiotherapy.
Additional material
Additional file 1: Figure S1 The effect of timing of BEZ235 and
BGT226 administration on tumor cell radiosensitivity. Clonogenic
survival assays of SQ20B and T24 cells treated as indicated. BEZ235 (50
nmol/L) and BGT226 (5 nmol/L) were added (A) immediately or (B) 6h
following irradiation (n = 3). *, P < 0.05; **, P < 0.01.
Additional file 2: Figure S2 BEZ235 radiosensitises tumor cells
under hypoxic conditions. A, clonogenic survival curves of cells treated
with 50 nmol/L BEZ235 and irradiation under hypoxic conditions. Cells
were incubated in hypoxia (0.5% O2) for 6 h. BEZ235 was then added at
1 h prior to irradiation and left for 17 h upon and the medium was
replaced. Cells were transferred to normoxia at 1 h post-irradiation. B,
clonogenic survival of cells after irradiation with 6 Gy and treatment with
50 nmol/L BEZ235 in oxic and hypoxic (0.5% O2) conditions, as described
above (A) and in Figure 1. *, P < 0.05; **, P < 0.01; *, P < 0.001 over
DMSO-treated control.
Additional file 3: Figure S3 Time-course of gH2AX foci in irradiated
tumor cells treatedwith BEZ235. FaDu and SQ20B cells were exposed
to 50 nmol/L BEZ235 for 1 h followed by irradiation with 4 Gy. Drugs
were left up to a maximum of 24 h. Residual gH2AX foci were counted
at the indicated time points. *, P < 0.05; **, P < 0.01; ***, P < 0.001 over
DMSO-treated control.
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